Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Celldex ( (CLDX) ) has provided an update.
On August 19, 2025, Celldex Therapeutics announced results from its Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE). The study met its primary endpoint by demonstrating significant mast cell depletion in the gastrointestinal tract. However, this did not translate into improved clinical outcomes, leading Celldex to halt further development of barzolvolimab for EoE. The company remains committed to advancing barzolvolimab in other conditions where mast cells play a crucial role, such as chronic urticaria and atopic dermatitis.
The most recent analyst rating on (CLDX) stock is a Buy with a $43.00 price target. To see the full list of analyst forecasts on Celldex stock, see the CLDX Stock Forecast page.
Spark’s Take on CLDX Stock
According to Spark, TipRanks’ AI Analyst, CLDX is a Neutral.
Celldex’s overall stock score is driven by positive technical momentum and supportive corporate events, despite significant financial challenges. The stock’s valuation is constrained by negative profitability metrics, but strategic corporate actions may support future growth.
To see Spark’s full report on CLDX stock, click here.
More about Celldex
Celldex Therapeutics is a company focused on developing novel antibody-based treatments that engage the human immune system to improve the lives of patients with allergic, inflammatory, and autoimmune disorders.
Average Trading Volume: 1,119,336
Technical Sentiment Signal: Hold
Current Market Cap: $1.69B
See more insights into CLDX stock on TipRanks’ Stock Analysis page.